Citigroup
PHAS

Citigroup’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Citigroup’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed – – 6175
2022
Q3 		$0 Sell
100
-5,900
-98% -$6.02K ﹤0.01% 6616
2022
Q2 		$4K Buy
+6,000
New +$5.74K ﹤0.01% 5751
2021
Q2 		– Sell
-1,042
Closed -$4K – 6537
2021
Q1 		$4K Sell
1,042
-1,455
-58% -$5.91K ﹤0.01% 5977
2020
Q4 		$8K Buy
2,497
+1,764
+241% +$6.32K ﹤0.01% 7023
2020
Q3 		$3K Sell
733
-1,390
-65% -$5.6K ﹤0.01% 7259
2020
Q2 		$10K Sell
2,123
-1,748
-45% -$7.74K ﹤0.01% 7070
2020
Q1 		$13K Buy
3,871
+1,119
+41% +$5.12K ﹤0.01% 6940
2019
Q4 		$17K Buy
2,752
+2,072
+305% +$8.54K ﹤0.01% 7007
2019
Q3 		$2K Sell
680
-3,164
-82% -$25.2K ﹤0.01% 7573
2019
Q2 		$50K Buy
+3,844
New +$47.1K ﹤0.01% 6484
2019
Q1 		– Sell
-113,605
Closed -$351K – 7881
2018
Q4 		$351K Buy
+113,605
New +$450K ﹤0.01% 4493

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup's PHAS Position: Q4 2022 in Review

Citigroup sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 100 shares.

Citigroup first reported a position in PHAS in Q4 2018 and held it in 11 quarters. The position peaked at $351K in Q4 2018. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Citigroup reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 100 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
  • Citigroup first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 11 quarters.
  • Citigroup's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $351K in Q4 2018.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.